Pfizer’s PhIII kidney cancer study for Inlyta flops as investigators flag a dead end on outcomes
Pfizer has lost out on a Phase III bid to revive flagging sales of its VEGF inhibitor Inlyta (axitinib).
Researchers say their drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
